Technologies | Scientific Publications

Initial results from a first in human phase 1 study of KVA12123, an anti-VISTA antibody, alone and in combination with pembrolizumab in patients with advanced solid tumors

AACR Annual Meeting 2025

Phase 1b Trial of IFx-Hu2.0, a novel in situ cancer vaccine, in checkpoint inhibitor-resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma

ASCO Annual Meeting 2024

First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0

AACR Annual Meeting 2024

VISTA as a mediator of immune suppression in AML initiated by DNMT3A and NPM1 mutations

66th American Society of Hematology (ASH) Annual Meeting, November 2024

VISTA: a potential new immune-oncology target in acute myeloid leukemia

65th American Society of Hematology (ASH) Annual Meeting, November 2023

Phase 1b trial of IFx-Hu2.0, a novel personalized cancer vaccine, in checkpoint inhibitor resistant Merkel cell carcinoma and cutaneous squamous cell carcinoma

2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2023

Tumor-specific antibody response induced by novel immunomodulator, IFx-Hu2.0, reflects extent of epitope spreading to multiple tumor epitopes

AACR Annual Meeting, 2022

Exosome packaging of emm55 mRNA

3rd Annual Exosome Based Therapeutic Development Summit 2021, November 2021

Anti‑tumor efficacy of plasmid encoding emm55 in a murine melanoma model

Cancer Immunology, Immunotherapy, June 2020

Trial in progress: IFx Hu2.0 (plasmid DNA coding for Emm55 streptococcal antigen in a cationic polymer) phase I first in human study for unresectable stage III or stage IV cutaneous melanoma

AACR Annual Meeting, 2020

First in human Phase I study using a plasmid DNA coding for Emm55 streptococcal antigen (IFx-Hu2.0) in patients with unresectable stage III or stage IV cutaneous melanoma

AACR Annual Meeting, 2019

Autologous Tumor Cells Engineered to Express Bacterial Antigens

Cancer Vaccines, 2014

Treatment of Metastatic Equine Melanoma with a Plasmid DNA Vaccine Encoding Streptococcus Pyogenes EMM55 Protein

Journal of Equine Veterinary Science, May 2014

Anti-tumor response induced by autologous cancer vaccine in canine lymphoma
Cancer Therapy, June 2008

Anti-Tumor Response Induced By Autologous Cancer Canine In Canine Lymphoma: A Case Study

Clinical Response to Multi-indication Intralesional Immunotherapy for Malignant Melanoma

T Cell Immune Response to Multi-Indication Intralesional Immunotherapy for Malignant Melanoma

Modular, disposable system to enable mass capture of circulating tumor cells

Clinical Phase I Trial: Intralesional Immunotherapy with IFx Hu2.0 (pAc/ emm55 ) Vaccine in Patients with Advanced Merkel Cell Carcinoma or Cutaneous Squamous Cell Carcinoma

Phase 1 Trial: Intralesional Immunotherapy with IFx-Hu2.0 Vaccine in Patients with Advanced Merkel Cell or Cutaneous Squamous Cell Carcinoma

[
IMMUNE FX
Bi-Functional ADC
Pipeline